Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study

Paul K Drain, Elena Losina, Sharon M Coleman, Janet Giddy, Douglas Ross, Jeffrey N Katz, Rochelle P Walensky, Kenneth A Freedberg, Ingrid V Bassett, Paul K Drain, Elena Losina, Sharon M Coleman, Janet Giddy, Douglas Ross, Jeffrey N Katz, Rochelle P Walensky, Kenneth A Freedberg, Ingrid V Bassett

Abstract

Background: A rapid diagnostic test for active tuberculosis (TB) at the clinical point-of-care could expedite case detection and accelerate TB treatment initiation. We assessed the diagnostic accuracy of a rapid urine lipoarabinomannan (LAM) test for TB screening among HIV-infected adults in a TB-endemic setting.

Methods: We prospectively enrolled newly-diagnosed HIV-infected adults (≥18 years) at 4 outpatient clinics in Durban from Oct 2011-May 2012, excluding those on TB therapy. A physician evaluated all participants and offered CD4 cell count testing. Trained study nurses collected a sputum sample for acid-fast bacilli smear microscopy (AFB) and mycobacterial culture, and performed urine LAM testing using Determine™ TB LAM in the clinic. The presence of a band regardless of intensity on the urine LAM test was considered positive. We defined as the gold standard for active pulmonary TB a positive sputum culture for Mycobacterium tuberculosis. Diagnostic accuracy of urine LAM was assessed, alone and in combination with smear microscopy, and stratified by CD4 cell count.

Results: Among 342 newly-diagnosed HIV-infected participants, 190 (56%) were male, mean age was 35.6 years, and median CD4 was 182/mm3. Sixty participants had culture-positive pulmonary TB, resulting in an estimated prevalence of 17.5% (95% CI 13.7-22.0%). Forty-five (13.2%) participants were urine LAM positive. Mean time from urine specimen collection to LAM test result was 40 minutes (95% CI 34-46 minutes). Urine LAM test sensitivity was 28.3% (95% CI 17.5-41.4) overall, and 37.5% (95% CI 21.1-56.3) for those with CD4 count <100/mm3, while specificity was 90.1% (95% CI 86.0-93.3) overall, and 86.9% (95% CI 75.8-94.2) for those with CD4 < 100/mm3. When combined with sputum AFB (either test positive), sensitivity increased to 38.3% (95% CI 26.0-51.8), but specificity decreased to 85.8% (95% CI 81.1-89.7).

Conclusions: In this prospective, clinic-based study with trained nurses, a rapid urine LAM test had low sensitivity for TB screening among newly-diagnosed HIV-infected adults, but improved sensitivity when combined with sputum smear microscopy.

Figures

Figure 1
Figure 1
Participant flow diagram.
Figure 2
Figure 2
Urine LAM and sputum smear microscopy (AFB) to diagnose tuberculosis among those who were either culture-confirmed (Figure 2a) or diagnosed with clinically suspected (Figure 2b) tuberculosis. a. Culture-confirmed Pulmonary Tuberculosis (N = 60). b. Clinically Suspected Tuberculosis (N = 92). Any participant who were LAM + but not diagnosed with culture-confirmed or clinically suspected tuberculosis are not depicted in these figures.
Figure 3
Figure 3
Post-test probability of tuberculosis when using a combined screening strategy of sputum AFB and urine LAM testing for various pre-test probabilities. Column A represents a cohort with 10% prevalence of tuberculosis; columns B and C represent the baseline prevalence of culture-positive pulmonary tuberculosis (17.5%) and clinically suspected tuberculosis (26.9%) that we observed in our cohort. Column D represents a cohort with a 40% prevalence of tuberculosis, which might occur among tuberculosis suspects in a highly endemic region.

References

    1. World Health Organization. Global tuberculosis control 2011. Geneva: World Health Organization; 2011.
    1. World Health Organization. Joint TB/HIV Interventions. Geneva: World Health Organization; 2009.
    1. World Health Organization. TB/HIV Working Group. Geneva; World Health: Priority research questions for HIV/TB in HIV-prevalent and resource-limited settings; 2010.
    1. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;14(14):1875–1880. doi: 10.1097/QAD.0b013e32832e05c8.
    1. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;14(7):823–829. doi: 10.1086/656282.
    1. Hassim S, Shaw PA, Sangweni P, Malan L, Ntshani E, Mathibedi MJ, Stubbs N, Metcalf JA, Eckes R, Masur H, Komati S. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis. 2010;14(7):1053–1059. doi: 10.1086/651119.
    1. Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, Aledort JE, Hillborne L, Rafael ME, Girosi F, Dye C. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006;14(Suppl 1):49–57.
    1. Saito S, Howard AA, Reid MJ, Elul B, Scardigli A, Verkuijl S, Nyaruhirira AU, Nash D. TB diagnostic capacity in sub-Saharan African health care settings. J Acquir Immune Defic Syndr. 2012;14(2):216–220. doi: 10.1097/QAI.0b013e3182638ec7.
    1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med. 2010;14(11):1005–1015. doi: 10.1056/NEJMoa0907847.
    1. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;14(9776):1495–1505. doi: 10.1016/S0140-6736(11)60438-8.
    1. World Health Organization. Global Plan to Stop TB 2011–2015. Geneva: World Health Organization; 2010.
    1. Stop TB Partnership & World Health Organization. An international roadmap for tuberculosis research: towards a world free of tuberculosis. Geneva: World Health Organization; 2011.
    1. Brennan PJ. Structure, function, and biogenesis of the cell wall of mycobacterium tuberculosis. Tuberculosis (Edinb) 2003;14(1-3):91–97. doi: 10.1016/S1472-9792(02)00089-6.
    1. Reither K, Saathoff E, Jung J, Minja LT, Saad E, Huggett JF, Ntinginya EN, Maganga L, Maboko L, Hoelscher M. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009;14:141. doi: 10.1186/1471-2334-9-141.
    1. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, Wong M, Luke B, Martin DJ, Chaisson RE, Dorman SE, Martinson NA. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr. 2009;14(2):145–151. doi: 10.1097/QAI.0b013e3181b98430.
    1. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010;14(3):e9848. doi: 10.1371/journal.pone.0009848.
    1. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012;14:103. doi: 10.1186/1471-2334-12-103.
    1. Alere Inc. Determine™ TB LAM test. USA: Waltham; 2013. . (accessed March 22, 2013)
    1. Meintjes G, Maartens G, Boulle A, Conradie F, Goemaere E, Hefer E, Johnson D, Mathe M, Moosa Y, Osih R, Rossouw T, van Cutsem G, Variava E, Venter WDF, Spencer D. on behalf of the Southern African HIV Clinicians Society. Guidelines for antiretroviral therapy in adults. S Afr J HIV Med. 2012;14(3):114–133.
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med. 2003;14(1):40–44. doi: 10.7326/0003-4819-138-1-200301070-00010.
    1. Liu TT, Wilson D, Dawood H, Cameron DW, Alvarez GG. Inaccuracy of death certificate diagnosis of tuberculosis and potential underdiagnosis of TB in a region of high HIV prevalence. Clin Dev Immunol. 2012;14:937013.
    1. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, Nicol MP. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013;14:407. doi: 10.1186/1471-2334-13-407.
    1. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;14(3):201–209. doi: 10.1016/S1473-3099(11)70251-1.
    1. Dorman S, Manabe Y, Nicol M, Nakiyingi L, Moodley M, Zemanay W, Holshouser M, Perkins M, Alland D, Ellner J. Accuracy of Determine TB-Lipoarabinomannan lateral flow test for diagnosis of TB and HIV+ adults. Seattle: 19th Conference on Retroviruses and Opportunistic Infection; 2012. Abstract #149aLB.
    1. Peter JG, Theron G, van Zyl SR, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalized patients. Eur Respir J. 2012;14:1211–1220. doi: 10.1183/09031936.00201711.
    1. Shah M, Martinson NA, Chaisson RE, Martin DJ, Variava E, Dorman SE. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Micro. 2010;14:2972–2974. doi: 10.1128/JCM.00363-10.
    1. Sun D, Dorman S, Shah M, Manabe YC, Moodley VM, Nicol MP, Dowdy DW. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. Int J Tuberc Lung Dis. 2013;14(4):552–558. doi: 10.5588/ijtld.12.0627.
    1. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012;14(13):1635–1643. doi: 10.1097/QAD.0b013e3283553685.

Source: PubMed

3
Iratkozz fel